Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
VBIO
Valion Bio, Inc.
CAPPED RATING
Valion Bio, Inc. (VBIO) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
C+
Factor Score
2.5
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
D
Factor Score
1.2
/ 5.0
Momentum
F
Factor Score
0.3
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
-1.0
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-88.4%
Price Return 12M
-99.1%
Catalyst Signal
0.00
Market Cap
$1.1M
TTM Revenue
-$86.0K
Price / Sales
-13.3
ROE
-459.5%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | C+ (2.5) | D (1.2) | F (0.3) | C+ (2.6) | D+ (1.8) |
| 2026-11-08 | C+ (2.5) | C+ (2.5) | D (1.2) | F (0.3) | C+ (2.6) | D+ (1.8) |
| 2026-11-01 | C+ (2.5) | C+ (2.5) | D (1.4) | F (0.3) | C+ (2.7) | C- (1.9) |
| 2026-10-25 | C+ (2.5) | C+ (2.5) | D (1.3) | F (0.3) | C+ (2.6) | D+ (1.8) |
| 2026-10-18 | C+ (2.5) | C+ (2.5) | D (1.3) | F (0.3) | C+ (2.6) | D+ (1.8) |
Page
1
of
3